Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169578 | 0.90 | CHRM2 (0.49) | POLBCYP4F2CYP4A11TSHRNPC1 | |
| SCHEMBL6035972 | 0.88 | POLB (0.68) | POLBCYP4F2CYP4A11TSHRNPC1 | |
| SCHEMBL1924061 | 0.86 | POLB (0.56) | POLBHTTKMT2AFFAR1ALDH1A1 | |
| SCHEMBL491098 | 0.85 | POLB (0.54) | POLBCYP4F2CYP4A11TSHRNPC1 | |
| SCHEMBL432804 | 0.85 | CYP4F2 (0.50) | POLBCYP4F2CYP4A11TSHRL3MBTL1 | |
| SCHEMBL3906109 | 0.85 | CYP4F2 (0.53) | POLBCYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL3903179 | 0.84 | CYP4F2 (0.52) | POLBCYP4F2CYP4A11TSHRNPC1 | |
| SCHEMBL435614 | 0.84 | CHRNA7 (0.55) | POLBCYP4F2CYP4A11ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL6983711 | 0.83 | CYP4F2 (0.48) | POLBCYP4F2CYP4A11TSHRMEN1 | |
| SCHEMBL13387961 | 0.83 | POLB (0.50) | POLBCYP4F2CYP4A11TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2914580-B1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-2632269-B1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9447044-B2 | Thioaryl derivatives as GPR120 agonists | LG LIFE SCIENCES LTD. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9221834-B2 | Cyclic amine substituted oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150291527-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2015-10-15 | — | — | US | disclosed |
| EP-2914580-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2015-09-09 | — | — | EP | disclosed |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1731505-A1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1698624-A1 | PHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1697339-A1 | 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005063729-A1 | 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291527-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GCGR | POLB 4859/4885CYP4F2 437/4885CYP4A11 414/4885 |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | GPR119, GPR55, GLP1R | POLB 4794/4885CYP4F2 2452/4885CYP4A11 350/4885 |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | GPR119, GPR55, FFAR1 | POLB 4738/4885CYP4F2 2383/4885CYP4A11 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.